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Abstract
Several recent reports have described a missense variant in the gene NR5A1 (c.274C>T;
p.Arg92Trp) in a significant number of 46,XX ovotesticular or testicular disorders of sex devel-
opment (DSDs) cases. The affected residue falls within the DNA-binding domain of the NR5A1
protein, however the exact mechanism by which it causes testicular development in 46,XX indi-
viduals remains unclear.Wehave screened a cohort of 26 patientswith 46,XX (ovo)testicularDSD
and identified three unrelated individuals with this NR5A1 variant (p.Arg92Trp), as well as one
patientwith a novelNR5A1 variant (c.779C>T; p.Ala260Val).Weexamined the functional effect of
these changes, finding that while protein levels and localization were unaffected, variant NR5A1
proteins repress the WNT signaling pathway and have less ability to upregulate the anti-testis
gene NR0B1. These findings highlight how NR5A1 variants impact ovarian differentiation across
multiple pathways, resulting in a switch from ovarian to testis development in genetic females.
K EYWORDS
46,XX ovotesticular DSD, 46,XX testicular DSD, disorders of sex development, NR5A1, SF1
1 INTRODUCTION
46,XX (ovo)testicular differences/disorders of sex development (DSDs;
MIM# 617480) are a rare group of phenotypes where the testic-
ular differentiation pathway is activated during development in a
46,XX individual, resulting in the formation of testes (46,XX testicu-
lar DSD) or ovotestes (46,XX ovotesticular DSD). Broadly, these con-
ditions are caused by gain-of-function variants in genes important for
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
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testis differentiation or loss-of-function variants in ovarian differen-
tiation genes (reviewed in Knarston, Ayers, & Sinclair, 2016). Up to
90% of 46,XX testicular DSDs (McElreavey, Vilain, & Abbas, 1993) and
10% of 46,XX ovotesticular DSDs (Vilain et al., 2011) are caused by
translocation of the Sex-determining region Y (SRY) gene, the initiating
gene for testis differentiation, onto the X chromosome (SRY-positive
46,XX DSD). Another common cause is ectopic SRY-box 9 (SOX9)
expression, often caused by duplications in the upstream enhancer
HumanMutation. 2018;1–10. wileyonlinelibrary.com/journal/humu 1
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(Croft, Ohnesorg, & Sinclair, 2018). Loss of function variants in
ovarian pathway genes (e.g., R-Spondin 1 [RSPO1]) have been iden-
tified in a small subset of syndromic 46,XX (ovo)testicular DSDs
(Bashamboo et al., 2018; Parma et al., 2006; Tomaselli et al., 2008).
Despite these known causes, SRY-negative 46,XX (ovo)testicular
DSDs have a diagnostic rate much lower than that of other DSDs
(Eggers et al., 2016) highlighting a need to identify novel genes
or genetic variants underlying these DSDs. Recently, five reports
have described a recurrent heterozygous variant in the Nuclear
Receptor Subfamily 5 Group A Member 1 (NR5A1) gene (c.274C>T;
p.Arg92Trp) in 12 cases of 46,XX (ovo)testicular DSD (Baetens et al.,
2017; Bashamboo et al., 2016; Domenice et al., 2016; Igarashi
et al., 2017; Takasawa et al., 2017), although the underlying mech-
anism for how this NR5A1 variant causes sex reversal in these
cases is still unclear. NR5A1, or steroidogenic factor-1 (SF1, Ad4BP;
MIM# 184757), is a nuclear receptor transcription factor with a
key regulatory role in development of the hypothalamus–pituitary–
gonadal and hypothalamus–pituitary–adrenal axes (Morohashi et al.,
1996; Parker et al., 1997; Val, Lefrancois-Martinez, Veyssiere, &
Martinez, 2003), and thus in the development of the male and female
gonads (reviewed in Ferraz-de-Souza, Lin, & Achermann, 2011; Lin
et al., 2008). Human variations in NR5A1 have been widely char-
acterized in 46,XY DSDs (gonadal dysgenesis, hypospadias, under-
virilization, and male infertility; Robevska et al., 2018; Ropke et al.,
2013) and 46,XX primary ovarian insufficiency (Voican et al., 2013)
and commonly show variable phenotypic expressivity and incom-
plete penetrance. In a recent study, we applied massively parallel
sequencing of a targeted gene panel to a DSD cohort, which included
26 patients with 46,XX (ovo)testicular DSD (Eggers et al., 2016). From
this study, we identified three new cases of 46,XX (ovo)testicular
DSD with the NR5A1 c.274C>T; p.Arg92Trp variant. Furthermore, we
report an additional NR5A1 variant, c.779C>T; p.Ala260Val, in a case
of 46,XX ovotesticular DSD. To our knowledge, this is the first instance
of anNR5A1 variant that does not affect codon 92 occurring in an indi-
vidual with 46,XX (ovo)testicular DSD. We have used protein model-
ing, protein localization, and luciferase assays to propose mechanistic
insights forNR5A1-mediated XX sex reversal in these cases.
2 METHODS
2.1 Ethical approval and patient recruitment
Patient recruitment, consent, and DNA extraction were carried out
as described previously (Eggers et al., 2016). Ethical approval for this
study was obtained from the Human Ethics Committee of the Fac-
ulty of Medicine at the Royal Children's Hospital, Melbourne, Victoria,
Australia (HREC22073).
2.2 Massively parallel sequencing
Total genomic DNA was sequenced on a targeted panel (HaloPlex,
Agilent, Santa Clara, CA) that includes 64 diagnostic DSD genes
(described in Eggers et al., 2016). This included six genes that have
been implicated in 46,XX (ovo)testicular DSD (FGF9, RSPO1, SOX3,
SOX9, SOX10, andWNT4). NR5A1 variant numbering is based on Gen-
Bank reference DNA sequence NM_004959.4, with the A of the ATG
initiation codon designated+1. NR5A1-predicted protein annotations
are based on NP_004950. Analysis for genomic modifiers was per-
formed by filtering variants using a list of 116 NR5A1-related genes
alongside our previously reported filtering criteria. The initial gene list
(N = 576) was compiled from data in STRING (https://string-db.org/)
andNR5A1 overexpression/knockdown assays (Doghman, Figueiredo,
Volante, Papotti, & Lalli, 2013), 116 of these genes were covered by
our targeted gene panel (N= 1,024).
2.3 In silico protein structure analysis
HOPE analysis was used to analyze the structural and functional con-
sequences of the variants identified (https://www.cmbi.ru.nl/hope/;
Venselaar, Beek, Kuipers, Hekkelman, & Vriend, 2010). We gener-
ated predictions of NR5A1 variant protein structure in silico using
I-TASSER, an online protein modeling server (https://zhanglab.ccmb.
med.umich.edu/ITASSER/; Roy, Kucukural, & Zhang, 2010; Zhang
et al., 2008). Predicted crystal structures were visualized using
PyMOL Molecular Graphics System v1.7.6.6 Enhanced for Mac OS X
(https://www.pymol.org).
2.4 Protein immunofluorescence
COS-7 cells were seeded onto eight-well chamber slides (Lab-Tek;
Brendale, Queensland, Australia) and transfected with NR5A1 expres-
sion vectors (WT, p.Arg92Trp, p.Ala260Val) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Following 24 hours of transfection, cells
were treated and analyzed as described previously (Robevska et al.,
2018).
2.5 Plasmid construction
Mutant NR5A1 expression vectors containing the p.Arg92Trp or
p.Ala260Val variants were created by site-directed mutagenesis
(QuikChange II XL Site-directedMutagenesis Kit; Agilent Technologies
Inc., Santa Clara, CA) according to themanufacturer's instructions (see
primer sequences in Supporting Information Table S1) using the mam-
malian expression vector pCMV6-Entry-hNR5A1 (RC207577; Ori-
GeneTechnologies Inc., Rockville,MD) as a template. The pGL4-hDAX1
reporter plasmid was generated via cloning of 994 bp of the pro-
moter region of the human NR0B1 gene (chrX:30327432–30328425)
into the pGL4.10.luc2 reporter plasmid (see primer sequences in
Supporting Information Table S1).
2.6 Luciferase assays
Luciferase reporter assays were performed in two cell lines (HEK
293-T or COS-7) in 96-well plates using Lipofectamine 2000 and the
Dual-LuciferaseReporter 1000Assay SystemKit (Promega; Fitchburg,
WI), with co-transfection of Renilla (pRL-TK) as a marker of trans-
fection efficiency. To assay the NR5A1-mediated transactivation of
mTESCO, COS-7 cells were co-transfected with a reporter construct,
pGL4-mTESCO (75 ng/well), pRL-TK (10 ng/well), SOX9 (50 ng/well),
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NR5A1 (WT, p.Arg92Trp, p.Ala260Val and p.Arg84His which was used
as a control; 50 ng/well), and FOXL2 (50 ng/well); cells were har-
vested 24 hours post transfection. The mTESCO reporter was used to
assay NR0B1-mediated repression of SOX9, as previously described
(Igarashi et al., 2017). InteractionofNR5A1withNR0B1was assayed in
HEK293-T cells using a pGL4-hDAX1 reporter as previously described
(Mizusaki et al., 2003). To assay the ability of NR5A1 proteins to regu-
late the canonical WNT pathway, we used the TOPFlash-TCF reporter
as previously described (Bashamboo et al., 2016). Luciferase activity
wasmeasuredonan InfiniteM200Proplate reader (Tecan;Männedorf,
Zürich, Switzerland); data represent the mean with standard error of
three independent experiments, each performed in triplicate.
3 RESULTS
3.1 Clinical phenotype
All of the individuals presentedhave a46,XXkaryotype (SRY-negative),
with varying degrees of virilization (Table 1). Patient 1 was born to
nonconsanguineous parents and recruited as an adult male with
azoospermia and bilateral testes; he had undergone an orchidopexy
in childhood. Patient 2 presented at birth with ambiguous genitalia,
a phallus measuring 2 cm, perineal urethral opening, and bilaterally
palpable gonads. Histological evaluation showed them to be bilat-
eral ovotestes. There were no Müllerian structures detected, and
testosterone production declined over time. The child underwent
orchidopexy and was raised as a female. Patient 3 presented with
virilization and was raised as a male; he had a micropenis (stretched
penile length of 3 cm at 5 years), hypospadias, and small underdevel-
oped scrotum with no evidence of Müllerian structures and a positive
testosterone response to stimulation. This individual also has a seizure
disorder managed by neurologists. Patient 4 was initially raised as
a male, then as female from 4 years of age. The patient presented
with ambiguous genitalia, a small phallus and vagina (4 cm deep),
with separate urethral and vaginal openings. The right gonad was an
ovotestis with sporadic germ cells in the tubules, calcifications, and
primordial follicles in ovarian part. The left gonad was ovarian tissue
with both primordial and developing follicles. Patients 1–3were found
to have normal adrenal function based on hormonal profiling at the
time of sample collection, these data were not available for Patient 4.
3.2 Identification of novel and known variants in
NR5A1 associatedwith 46,XX (ovo)testicular DSD
46,XX (ovo)testicular DSD cases were screened using two assays.
Patient DNA was run on our custom multiplex ligation-dependent
probe amplification (MLPA) assay (previously described in Ohnesorg
et al., 2017), which screens 10 genes implicated in DSD for copy num-
ber variants, including four probes in the enhancer region of SOX9. The
MLPA showed that Patients 1–4 are negative for common copy num-
ber variants in known DSD genes. We then performed massively par-
allel sequencing on a targeted DSD gene panel (previously described
in Eggers et al., 2016) to screen the patients for single nucleotide vari-
ants and small insertions/deletions in 64 diagnostic DSD genes. A pre-
viously reported variant in exon 4 ofNR5A1 (NM_004959.4:c.274C>T,
p.Arg92Trp; Baetens et al., 2017; Bashamboo et al., 2016; Igarashi
et al., 2017) was identified in three cases of 46,XX (ovo)testicular DSD
(Table 2; Patients 1–3). The change was found to be maternally inher-
ited in Patient 3. The mother was subfertile, having 4–6 menses per
year and had difficulty falling pregnant. Interestingly, the maternal
aunt and uncle of Patient 3 also experienced fertility issues. A further
variant (NM_004959.4:c.779C>T, p.Ala260Val) was found in exon 4
of NR5A1 in a single case of 46,XX ovotesticular DSD (Patient 4). The
NR5A1p.Ala260Val variantwas extremely rare in the population (gno-
mAD frequency: 4.13e-6) and predicted to be damaging in two of the
four in silico algorithms used. It has been previously implicated in 46,XY
DSD (Chan et al., 2015). These two NR5A1 variants were found in het-
erozygous form and flagged for functional validation.
3.3 NR5A1 variants have unaffected protein
expression and subcellular localization
To assess whether the NR5A1 variants affected protein localization
or expression, we used immunofluorescence staining (Figure 2b).
The wild-type and p.Arg92Trp variant NR5A1 protein showed strong
nuclear expression with nucleolar exclusions (Figure 2b: ii and iv), con-
sistent with previous reports (Baetens et al., 2017; Kohler et al., 2008).
We showed that the p.Ala260Val variant NR5A1 protein exhibits
similar levels of expression and nuclear localization (Figure 2b: vi). To
elucidate how the amino acid substitutions may affect function, we
undertook protein structure modeling. At codon 92 of NR5A1, the
wild-type arginine falls within the highly conserved and functionally
critical DNA binding domain (Figure 1a,b). As described previously,
the substitution of an arginine to tryptophan at position 92 leads
to a change in charge (from positive to neutral) as well as a loss of
hydrogen bond formation potential (due to size difference between
the residues; Figure 2a: i and ii; Baetens et al., 2017; Bashamboo et al.,
2016; Domenice et al., 2016; Igarashi et al., 2017). Together these
may affect the protein's ability to interact with DNA. At codon 260 of
NR5A1, the wild-type alanine falls within the evolutionary conserved
alpha helix 3, part of the ligand binding domain (Figure 2a: iii). This
alanine residue is predicted to be on the surface of the protein and
replacement with a larger valine may affect interactions between
NR5A1 and other molecules (Figure 2a: iv).
3.4 NR5A1 variants show decreased activation
ofmale pathway
It has been previously shown that the NR5A1 p.Arg92Trp variant has
reduced ability to upregulate male pathway genes (Sox9, Anti Mul-
lerian hormone [Amh], Cytochrome P450 Family 11 Subfamily A Mem-
ber 1 [Cyp11a1]; Bashamboo et al., 2016). We wondered if our new
variant may show an increased ability to upregulate the testis path-
way. To address this, we tested the two NR5A1 variants on their abil-
ity to upregulate the Sox9 enhancer mTESCO, as well as a previously
characterized loss of function variant (p.Arg84His) from a 46,XY DSD
patient as a positive control (Robevska et al., 2018).We found that like
the NR5A1 p.Arg92Trp variant, the p.Ala260Val variant also results
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in decreased ability to transactivate this male pathway promoter
(Figure 3a). This loss of activation was also evident in the presence of
the SOX9-inhibiting factor Forkhead Box L2 (FOXL2), indicating that
the variantNR5A1 proteins do not affect the FOXL2-mediated repres-
sion of SOX9 (Figure 3a).
3.5 NR5A1 variants alter ovarian pathway
activation via reducedWNT signaling activity
As the above assay does not explain why the male pathway is acti-
vated and ovarian pathway repressed in these 46,XX (ovo)testicular
patients, we turned to female pathways. Previous functional assays
on the NR5A1 p.Arg92Trp variant show disruption to both ovarian
and testicular pathways (Bashamboo et al., 2016; Igarashi et al., 2017).
NR0B1 is a key gene involved in repression of the testis pathway; its
dysregulation may explain these XX phenotypes. In ovarian develop-
ment, NR5A1 transactivation of SOX9 is repressed byNR0B1 (Igarashi
et al., 2017; Ludbrook et al., 2012) proposed thatmutantNR5A1 is less
responsive to NR0B1. We assessed this by co-transfecting HEK 293-T
cells withNR0B1, SOX9, andNR5A1 constructs aswell as themTESCO
Sox9 enhancer (Figure 3b). In the presence of wild-type NR5A1 and
SOX9, addition of NR0B1 resulted in dosage-dependent repression
of Sox9 mTESCO. Similarly, using both mutant forms of NR5A1, Sox9
mTESCO was also repressed in a NR0B1-dosage-dependent manner
(Figure 3b), although the initial activation of the reporterwas lower for
both variants as seen in Figure 3a. Thus, these variants are still respon-
sive to NR0B1-mediated repression of SOX9.
Bashamboo et al. (2016) also investigated NR0B1 dysregulation.
In the developing gonad, the NR5A1/𝛽-catenin complex upregulates
several targets such as DSS-AHC critical region on the X chromo-
some protein 1 (DAX1; encoded by NR0B1) (Mizusaki et al., 2003).
It has been suggested that mutant NR5A1 causes dysregulation of
NR0B1 and thus loss of SOX9 repression in XX gonads (Bashamboo
et al., 2016). We assessed the effect of mutant NR5A1 on NR0B1-
mediated repression of SOX9. To assay any direct effect of these vari-
ants on the NR0B1 promoter, we used a reporter construct containing
the upstream NR0B1 promoter region (994 bp). HEK 293-T cells were
co-transfected with this NR0B1 reporter and constructs for wild-type
and variant NR5A1 (Figure 3c). Wild-type NR5A1 upregulated NR0B1
promoter activity and both NR5A1 variants showed similar upregula-
tion of the NR0B1 promoter, consistent with the above assay showing
that the variants do not change NR5A1-mediated NR0B1 repression
of SOX9. To test the NR5A1/𝛽-catenin complex in NR0B1 upregula-
tion, we introduced 𝛽-catenin. 𝛽-catenin andwild-typeNR5A1 showed
a fivefold increase in NR0B1-reporter activity compared the empty
vector controls, but the patient variants significantly repressed this
activity (Figure 3d). To further test whether the NR5A1 variants are
repressing the WNT/𝛽-catenin pathway, we looked at the effect of
wild-type and variant NR5A1 on canonical WNT activity using the
TOPFlash reporter system (Figure 3e). The TOPFlash reporter shows a
20-fold induction upon the transfection of thewild-type 𝛽-catenin con-
struct. Introduction of the wild-type NR5A1 repressedWNT signaling
activity induced by 𝛽-catenin, and we found that both variant forms of
NR5A1 repressed this further (P < 0.0001). As both variants present
in the patient are heterozygous, we also transfected each variant with
an equal amount of wild-type construct. Increased repression ofWNT
signalingwas still observedwhen each variant NR5A1was transfected
with or without the wild-type form, indicating some dominant nega-
tive effect of the variant allele on theWT. Taken together, these results
indicate that variants in NR5A1 show no reduced NR0B1-dependent
repression of SOX9 expression or changes in NR0B1 promoter acti-
vation, yet these variants have increased repression of the ovarian-
specificWNT signaling pathway. This may underlie testis development
in an XX background.
3.6 Additional genomic variantsmay contribute to
oligogenic inheritance
Given the wide phenotypic variation observed in individuals with
NR5A1 variants, recent reports hypothesize that oligogenic inheri-
tance is likely to be at play (Camats, Fernandez-Cancio, Audi, Schaller,
& Fluck, 2018; Robevska et al., 2018). We filtered our massively paral-
lel sequencing data with a list of 116 NR5A1-related genes to identify
variants that may act additively with the NR5A1 variants in these four
patients. Sixteen NR5A1-associated variants were identified and sum-
marized in Supporting Information Table S2. In Patient 1, variantswere
found in CREBBP, GDF9, HSD3B1, STAR, and TG. Patient 2 had variants
in AR, DACH1, and ZFPM2. Patient 3 had two NR5A1-related variants;
these were in the FRAS1 and MTSS1 genes. Patient 4 had variants in
BMP15,MSX2, PGR, POR, PTCH1, and RARA.
4 DISCUSSION
During gonadal differentiation, NR5A1 is involved in both activation
and repression of the testis pathway. Variants in the NR5A1 gene can
cause a wide variety of DSDs including 46,XY gonadal dysgenesis,
46,XX premature ovarian insufficiency, and recently a single vari-
ant (p.Arg92Trp) has been implicated in 46,XX (ovo)testicular DSD
(Baetens et al., 2017; Bashamboo et al., 2016; Domenice et al., 2016;
Igarashi et al., 2017; Takasawa et al., 2017). The exact mechanism by
which this variant activates testis development in a 46,XX individual
remains elusive. Here, we have described three patients with 46,XX
(ovo)testicular DSD carrying this variant, and in addition, describe a
patient with 46,XX ovotesticular DSD with a novel NR5A1 variant,
p.Ala260Val.
As the gonads first begin to differentiate, it is the presence of the
Y-linked SRY gene that activates the male genetic pathway, driving dif-
ferentiation of the testicular Sertoli cells. However, we know that acti-
vation of the testis pathway by SRY can be bypassed if SOX9, the factor
immediately downstream of SRY, is upregulated (Huang, Wang, Ning,
Lamb, & Bartley, 1999; Vidal, Chaboissier, de Rooij, & Schedl, 2001).
NR5A1 is a known regulator of SOX9, thus aberrant activation of the
male pathway byNR5A1p.Arg92Trpwas investigated as a cause of sex
reversal. Previous functional analyses suggest that NR5A1 p.Arg92Trp
cannot activate testicular development viamale pathway genes includ-
ing Sox9, Amh, and Cyp11a1 (Bashamboo et al., 2016). Instead these
variants lose male-pathway regulatory ability, this is consistent with
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TABLE 2 NR5A1 variants identified in 46,XX (ovo)testicular DSD cases
Patient
ID Gene DNA change
Protein
change Zygosity Inheritance
Previous
publications/
reports In silico
1 NR5A1 c.274C>T p.Arg92Trp Heterozygous N/A Baetens et al., 2017;
Bashamboo et al.,
2016; Igarashi
et al., 2017
Damaging
2 NR5A1 c.274C>T p.Arg92Trp Heterozygous N/A Baetens et al., 2017;
Bashamboo et al.,
2016; Igarashi
et al., 2017
Damaging
3 NR5A1 c.274C>T p.Arg92Trp Heterozygous Maternal Baetens et al., 2017;
Bashamboo et al.,
2016; Igarashi
et al., 2017
Damaging
4 NR5A1 c.779C>T p.Ala260Val Heterozygous N/A Chan et al., 2015
gnomAD
frequency: 4.13×
10–6
Two of 4 but
previously
found to be
damaging.
In silico:PolyPhen2,MutationTaster, SIFT, LRT; Damaging: deleterious or possibly deleterious in 4/4 predictors; N/A, not available. DNAmutation numbering
is based onGenBank referenceDNA sequenceNM_04959.4, with the A of the ATG initiation codon designated+1. Predicted protein annotations are based
onNP_004950.
F IGURE 1 Variants in NR5A1 identified in a cohort of individuals with 46,XXDSD. (a) Schematic representation of the predicted protein
structure of NR5A1 showing the approximate location of the two variants identified in a cohort of individuals with 46,XXDSD. The protein
domains are as follows: DNA binding domain (DBD) containing two zinc finger motifs (Zn) and the Fushi-tarazu factor 1 box (Ftz-F1), the hinge
region, and ligand binding domain (LBD). P-Box, T-box, A-box, as well as two activational domains—AF1 and AF2. (b) Evolutionary conservation of
the NR5A1 protein sequence around the twomissense variants identified in our cohort
the fact that these variants have also been described in 46,XY DSD
(Bashamboo et al., 2016; Chan et al., 2015) where activation of testis
differentiation is lost and ovarian development takes over. Consistent
with these results, we found that neither the p.Arg92Trp variant nor
the novel p.Ala260Val variant had increased SOX9 activation, thus in
vitro there is no evidence forNR5A1 variants abnormally activating the
testis pathway.
When no Y-chromosome is present, the male pathway is not acti-
vated, allowing a female specific pathway to drive ovarian differenti-
ation, and repress testis development. The NR0B1 gene is involved in
repression of the testis pathway and its dysregulationmayunderlie the
sex reversal reported in these cases. NR5A1 transactivates SOX9, and
in ovarian development, this is antagonized byNR0B1 (Ludbrook et al.,
2012). Igarashi et al. (2017) proposed that the NR5A1 p.Arg92Trp
mutant is unresponsive to NR0B1, resulting in a loss of SOX9 repres-
sion in 46,XX (ovo)testicular DSD cases. By contrast, we showed that
both forms of mutant NR5A1 are still responsive to NR0B1 and still
allow repression of SOX9 activity, suggesting that this anti-testis inter-
action is maintained in the 46,XX DSD patients. These contradictory
results may be in part due to different cell types being used, perform-
ing this assay in the native (human fetal ovary) cells would be nec-
essary to establish whether NR0B1 de-repression is truly playing a
role in these phenotypes. Bashamboo et al. (2016) proposed an alter-
nate mechanismwhereby the NR5A1 p.Arg92Trp variant has less abil-
ity to upregulate the anti-testis NR0B1, perhaps via a loss of synergy
with 𝛽-catenin. Ultimately, this would mean that testis factors, such
as SOX9, are no longer suppressed. We found that both NR5A1 vari-
ants showed similar activation of the NR0B1 promoter. However, we
KNARSTON ET AL. 7
F IGURE 2 Protein conformation and cellular expression. (a) To investigate the potential effect of the variants on protein conformation, we
performed an in silico prediction with the wild-type NR5A1 and both variants using I-Tasser and PyMol modeling. (a: i and ii)Wild-type arginine
(Arg, R) at position 92 falls within the DNA binding domain of the protein. Themutant tryptophan (Trp,W) is larger than the arginine and has less
hydrogen bonding potential. (a: iii and iv) The residue at position 260 falls within alpha helix 3 of the ligand binding domain. The wild-type alanine
(Ala, A) is smaller than themutant valine (val, V), this is located on the protein surface. (b) Protein expression of both variant andwild-type NR5A1
was assessed in COS-7 cells with anNR5A1 antibody (green). Cells were transfectedwith an equal amount of NR5A1 expression vector (wild-type
or variant). Nuclear counterstaining was performedwith DAPI (blue).Wild-type NR5A1 showed strong nuclear staining with nucleolar exclusions
(b: i and ii). The variant NR5A1 protein expression and localization was unaffected (b: iii–vi)
did find that compared to wild-type, the two variants repressed the
𝛽-catenin-mediated activation of this promoter construct, indicating a
repression of WNT signaling might be at play. In ovarian differentia-
tion, NR5A1 is also necessary for induction of female pathway genes
Wnt4 and Rspo1 (Combes et al., 2010). Bashamboo et al. (2016) previ-
ously found that the NR5A1 p.Arg92Trp mutant has reduced synergy
with 𝛽-catenin and loses WNT signaling activation compared to wild-
type NR5A1. We have found that in vitro wild-type NR5A1 represses
𝛽-catenin-mediated WNT signaling, and that this repression was sig-
nificantly enhanced by both patient variant NR5A1 forms. This vari-
ation in wild-type NR5A1 activity (Figure 3e vs. Bashamboo et al.,
2016) suggests that theNR5A1/𝛽-catenin complexhasboth repressive
and activating effects on WNT signaling, these could be influenced by
factors such as subtle changes in gene dosage or environment. Being
able to investigate these interactions in more standardized cellular
assays or cell types more closely resembling human embryonic gonad
may help to increase reproducibility of such findings in future. Over-
all, our findings highlight that increased repression of WNT/𝛽-catenin
signaling resulting in reducedNR0B1, and thus reduced testis pathway
repression,mayunderlie the inhibition of ovarian development and the
formation of testis tissue in these 46,XX patients.
Given the large number of known target genes for NR5A1, there
are likely to be other signaling pathways not investigated here that
are affected in these patients, however the inaccessibility of gonadal
tissue makes this difficult to assess. Studying additional individuals
with these variants may improve our understanding of possible mech-
anisms. Of interest, a second heterozygous variant at codon 92 with a
different amino acid change (p.Arg92Gln) has been found in46,XX indi-
viduals with adrenal insufficiency with or without ovotesticular DSD
(Guran et al., 2016; Swartz et al., 2017). The NR5A1 p.Arg92Gln vari-
ant shows partial loss of activation of NR5A1 target gene promot-
ers (including Amh, Cyp11a1, Cyp19a1, and Insl3; Lin et al., 2007) but
does not show loss of synergy with 𝛽-catenin and reduced WNT sig-
naling like the p.Arg92Trp variant does (Bashamboo et al., 2016). Also,
the presence of adrenal phenotypes associated with the p.Arg92Gln
variant only suggests that this residue change impacts different tar-
get genes to the p.Arg92Trp variant, however long term follow up of
cases are necessary as adrenal insufficiencymay not present until later
in life. This highlights how sequence variation at the A-box motif in
NR5A1 can impact binding specificity to target genes; DNA binding
studies comparing these mutant proteins with wild-type NR5A1 could
confirm this.
46,XX individuals with the NR5A1 p.Arg92Trp variant cover a wide
phenotypic spectrum, for example, gonadal phenotypes include nor-
mal ovary, streak gonad, and testis (Baetens et al., 2017; Bashamboo
et al., 2016; Igarashi et al., 2017). Incomplete penetrance and variable
expressivity are well established features of NR5A1-associated disor-
ders, this is because adreno-gonadal development is exquisitely sensi-
tive to changes inNR5A1 gene dosage (Val,Martinez-Barbera, & Swain,
2007) and may be subject to genetic or environmental modifiers. A
recent paper reported a 46,XX sibling pair each with the heterozygous
NR5A1 p.Arg92Trp variant displaying markedly different phenotypes,
which indicates that environment is an important modifier (Taka-
sawa et al., 2017). Furthermore, these variants are absent or at low
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F IGURE 3 NR5A1mutants show altered function in luciferase assays using sex differentiation-specific reporters. (a) Both NR5A1 variants as
well as a positive control variant (loss of function from 46,XYDSD) show decreased transactivation of SOX9mTESCOwhen co-transfected into
COS-7 cells with SOX9. This is also observedwhen the female pathway SOX9 repressor, FOXL2, is also transfected. (b) Co-transfection of HEK
293-T cells with NR5A1, SOX9, and increasing concentrations of NR0B1 showed that mutant NR5A1 does not affect NR0B1-mediated repression
of SOX9. SOX9 activity wasmeasured using the TESCO reporter. (c) Co-transfection of COS-7 cells with wild-type ormutant NR5A1 shows no
change in activity of the NR0B1 promoter for both NR5A1mutants (d) Co-transfection of COS-7 cells with wild-type ormutant NR5A1 and
𝛽-catenin results in repression of the NR0B1 promoter for both NR5A1mutants. (e) TOPFlash activation is reducedwhenHEK 293-T cells are
transfected with 𝛽-catenin andmutant NR5A1 compared to wild-type NR5A1. Data represent themeanwith the standard error of three
independent experiments performed in triplicate. An unpaired t-test was applied to obtain P-values, ****P< 0.0001; ***P< 0.001; **P< 0.01;
*P< 0.05; ns= P> 0.05
frequency in large population databases (e.g., gnomAD) and individuals
with the NR5A1 p.Arg92Trp variant have diverse ethnic backgrounds,
including African, Hispanic, European, and Asian, suggesting that the
variable phenotypic expressivity observed is not a product of founder
effect or genetic background. Additional genomic variants may act as
modifiers of expression and thus explain some of the variable expres-
sivity observed. A recent report on 46,XY DSDs with NR5A1 variants
explored oligogenic inheritance by filtering exome sequencing vari-
ants with a list ofNR5A1-associated genes (Camats et al., 2018). Using
a similar, albeit targeted, approach, we identified an additional 2–6
variants per patient that may modify NR5A1 expression or act addi-
tively withNR5A1 to generate thewide phenotypic variation observed
(Supporting Information Table S2). For example, Patient 4 had a het-
erozygous variant in Cytochrome P450 Oxidoreductase (POR; MIM#
613571) in addition to the NR5A1 p.Ala260Val variant. Variants in
this gene are associated with genital anomalies, and combined POR
(NM_000941.2:c.1370 G>A; p.Arg457His) and NR5A1 (p.Arg92Trp)
variants have been reported in a case of 46,XX testicular DSD before
(Igarashi et al., 2017). Given that NR5A1 and POR are both involved
in steroidogenesis, these two variants may have an additive effect on
steroidogenic function; this may apply to other variants we report in
known steroidogenic genes including STAR, PTCH1, andHSD3B1. Func-
tional assessment would be required to confirm their pathogenicity
and interaction with NR5A1 in these phenotypes. In future, exome
sequencing on these and additional individuals (affected and unaf-
fected) with NR5A1 variants would enable a genome-wide and unbi-
ased approach to investigating oligogenic inheritance.
In our cohort of patients with SRY-negative 46,XX (ovo)testicular
DSD, NR5A1 variants contribute to 15% (4/26) of cases. This is com-
parable to SOX9 enhancer duplications, which underlie 19% (5/26) of
cases in this cohort (Croft et al., 2018; Ohnesorg et al., 2017). Conse-
quently,NR5A1genevariants shouldbe consideredan important cause
underlying cases of SRY-negative 46,XX (ovo)testicular DSDs. Screen-
ing for NR5A1 gene variants should be included in routine genetic
testing for these patients.
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